Biomerica files for FDA Emergency Use Authorization (EUA) of its Unique Laboratory Antibody Test for COVID-19

IRVINE, Calif., June 16, 2020 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) announced today they have submitted to the FDA an EUA application for an ELISA lab-based serology blood test for the detection of antibodies that identify if a person has been infected with the novel coronavirus (COVID-19).  Antibody testing can be an important next step in opening the economy to tell people if they have been previously infected.  This is the third COVID-19 antibody test introduced by the Company. The other two, which are finger-prick rapid tests, are actively being sold outside of the US and have been well received.  The Company also intends to obtain a CE mark to market and sell this ELISA laboratory test outside the US.